ABSTRACT

[Abstract] Objective To explore the effect of venlafaxine on sudden deafness complicated with anxiety and depression.
Methods 104 patients with sudden deafness combined with anxiety and depression admitted to our hospital from August 2022 to August 2024 were selected. All patients were given conventional symptomatic treatment, the control group were given relaxation training, and the observation group was given venlafaxine orally on the basis of the control group. The anxiety and depression mood, clinical efficacy, serum 5-hydroxytryptamine (5-HT) and neuropeptide Y (NPY) levels, psychological resilience score, coping style score, sleep quality score, quality of life score and adverse reactions were compared in both groups.
Results After treatment, anxiety score (SAS), depression score (SDS) of both groups were decreased, and the observation group was lower (P<0.05). After treatment, the total effective rate of observation group was higher than that of control group (P<0.05). Serum 5-HT and NPY levels were increased in both groups, and observation group was higher (P<0.05). Connor davidson resilience scale (CD-RISC) score and simple coping style questionnaire (SCSQ) positive coping score were increased in both groups, and higher in observation group (P<0.05). Pittsburgh sleep quality index (PSQI) score decreased in both groups, and the observation group was lower, and WHO quality of life measurement scale brief version (WHOQOL-BREF) score increased in both groups, and the observation group was higher (P<0.05). There was no difference in the incidence of adverse reactions in both groups (P>0.05).
Conclusion   Venlafaxine can improve anxiety and depression, reduce clinical symptoms, improve psychological status, regulate neurotransmitter levels, and improve sleep and quality of life in sudden deafness patients with anxiety and depression.

Key words: [Key words] Sudden deafness; Venlafaxine; Anxiety; depressed; 5-hydroxytryptamine; Neuropeptide Y